Respiratory      Neonatology                                                                                                                                                                               
  • Home
  • |
  • Contacts
  • |
  • Customer Letter
  • |
  • Pharmacovigilance
  • |
  • Chiesi Group
  • CN
  • EN

Enter at least 3 characters
  • About us
    • Our company
    • Our history
    • Chiesi globally
    • Values
    • B Corp and Benefit Society
  • Therapeutic areas
    • Respiratory
    • Neonatology
  • Products
  • Research and development
    • Pipeline
    • Production plants
  • Career development
    • Leading quality
    • Sincere cooperation
    • People first
    • Welfare constant companion
    • Recruit
  • Media
    • News and press release
    • -
    • -
    • ”Silent Killer“——Attention should be paid to the risk management of acute exacerbation of chronic obstructive pulmonary disease
    • Financial Report | Casey Group's International Market Business, including China, Continues to Grow in 2022
    • Hand in hand with the "Desert Lock Border Forest Action"
    • -
    • -
    • -
    • -
    • Chiesi earns B Corp Certification Again, Sets More Challenging 2025 Action Goals
    • To build a healthier and more sustainable future, Chiesi continues to promote related initiatives
    • -
    • -
    • -
    • -
    • -
    • -
    • Chiesi_Bayer_China_Parternship_PressRelease
HOME > Chiesi Press Release > none
  • Media
  • News and press release
  • -
  • -
  • ”Silent Killer“——Attention should be paid to the risk management of acute exacerbation of chronic obstructive pulmonary disease
  • Financial Report | Casey Group's International Market Business, including China, Continues to Grow in 2022
  • Hand in hand with the "Desert Lock Border Forest Action"
  • -
  • -
  • -
  • -
  • Chiesi earns B Corp Certification Again, Sets More Challenging 2025 Action Goals
  • To build a healthier and more sustainable future, Chiesi continues to promote related initiatives
  • -
  • -
  • -
  • -
  • -
  • Chiesi_Bayer_China_Parternship_PressRelease

none

-

© 2023 Chiesi Pharmaceutical (Shanghai) Co., Ltd
Unit 601、602、603、605、606,Building 3, Lane 1398,Kaixuan Road Shanghai 200052
Telephone +86 21 52588899
E-mail info.cn@chiesi.com
  • Sitemap
  • Cookies
  • Credits
  • Terms of use
  • Chiesi Code of Interdependence
  • SPEAKUP&BEHEARD
  • Chiesi Code of Interdependence
  • Terms of use
  • Privacy
  • -
  • SPEAKUP & BEHEARD
CHIESI ON THE WEB
CHIESI ON THE WEB
Belgique
Chiesi sa
Brésil
Chiesi Farmacêutica Ltda
Bulgarie
Chiesi Bulgaria Ltd.
Chine
Chiesi Pharmaceutical (Shanghai) Co., Ltd
Allemagne
Chiesi GmbH
Grèce
Chiesi Hellas Pharmaceuticals S.A.
Royaume Uni
Chiesi Ltd
Italie
Divisione Farmaceutica Italia
Mexique
Chiesi Mexico S.A. de C.V.
Pays-Bas
Chiesi Pharmaceuticals B.V.
Autriche
Chiesi Pharmaceuticals GmbH
Pakistan
Chiesi Pharmaceuticals (Pvt) Limited
Pologne
Chiesi Polonia
Roumanie
Chiesi România S.r.l.
La Fédération de Russie
Chiesi Pharmaceuticals LLC
Suède
Chiesi Pharma AB
Slovaquie
Chiesi Slovakia s.r.o
Slovénie
Chiesi Slovenija, d.o.o
Espagne
Chiesi España S.A.
République Tchèque
Chiesi CZ s.r.o.
Turquie
Chiesi İlaçTicaret Limited Sirketi  A.Ş.
Hongrie
Chiesi Hungary Kft.
Etats-Unis
Chiesi Usa Inc.